Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Liver Transplant Recipients with 18F-FDG-avid Hepatocellular Carcinoma (EVEREST-LT)
KCT0012405Phase 2Not yet recruiting
- Sponsor
- Chong Kun Dang
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in hepatocellular carcinoma (HCC), sponsored by Chong Kun Dang. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0012405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012405.